Omnicell (NASDAQ:OMCL) Releases FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 1.650-1.850 for the period, compared to the consensus estimate of 1.790. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Stock Up 1.9 %

OMCL stock opened at $40.16 on Friday. The company’s 50-day moving average price is $44.21 and its 200 day moving average price is $43.29. The company has a current ratio of 1.37, a quick ratio of 0.95 and a debt-to-equity ratio of 0.13. The company has a market cap of $1.86 billion, a P/E ratio of 148.75, a P/E/G ratio of 26.98 and a beta of 0.78. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, research analysts expect that Omnicell will post 1.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

OMCL has been the subject of a number of analyst reports. Bank of America cut their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Benchmark reaffirmed a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday. Barclays increased their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. JPMorgan Chase & Co. raised their target price on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Finally, Craig Hallum lifted their price target on shares of Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $52.33.

Insider Activity

In related news, Director Mark W. Parrish sold 12,000 shares of Omnicell stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the sale, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.